FOLH1 and Familial prostate cancer: With a view to developing a molecular [188Re]Re-labeled agent for PSMA PRRT, we further characterized the biodistribution profiles of [188Re]Re-DP1-PSMAt and [188Re]Re-DP2-PSMAt in male athymic nude mice bearing LNCaP xenografts (Fig. 4), which recapitulate clinical metastatic prostate cancer more closely than DU145-PSMA+ xenografts.